Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features

The infection caused by methicillin-resistant Staphylococcus aureus (MRSA) is a global threat to public health. Vancomycin remains one of the first-line drugs for the treatment of MRSA infections. However, S. aureus isolates with complete resistance to vancomycin have emerged in recent years. Vancomycin-resistant S. aureus (VRSA) is mediated by a vanA gene cluster, which is transferred from vancomycin-resistant enterococcus. Since the first VRSA isolate was recovered from Michigan, USA in 2002, 52 VRSA strains have been isolated worldwide. In this paper, we review the latest progresses in VRSA, highlighting its resistance mechanism, characteristics of VRSA infections, as well as clinical treatments.

• NN
  National Natural Science Foundation of China

  Awards: 81471993, 81672071
• DO
  Department of Science and Technology of Sichuan Province

  Award: 2019YJ0693
• SM
  Southwest Medical University

  Award: 2018XYLH-017
• FA
  First Affiliated Hospital, Liaoning Medical University

  Award: 2018XYLH-017